Home › Funds › Intermede Investment Partners Ltd › VRTX

Intermede Investment Partners Ltd position in VRTX

VERTEX PHARMACEUTICALS INC · Health Care

Intermede Investment Partners Ltd reported holding 101,619 shares of VRTX (VERTEX PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$51.5M, representing 2.17% of its reported portfolio and ranking #22 among its reported holdings. Intermede Investment Partners Ltd has disclosed VRTX holdings in 6 of the last 6 reported quarters, going back to Q1 2025.

Latest position (Q2 2026)101.62K sh
Reported value held$51.50M
Portfolio Weight2.17%
First reportedQ1 2025
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Intermede Investment Partners Ltd's VRTX position evolved

Intermede Investment Partners Ltd first disclosed a stake in VRTX in Q1 2025 at 204,045 shares (US$98.9M). Across 6 filings, Intermede Investment Partners Ltd increased the stake 0 time(s), trimmed it 5 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 101,619 shares valued at US$51.5M — a reduction of -4,751 shares quarter over quarter.. Notable position changes include a 28% trim in Q3 2025 (shares rose 16% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2025 204.04K $98.92M New
Q2 2025 193.91K $86.33M Reduce
Q3 2025 140.02K $54.84M Reduce
Q4 2025 133.38K $60.47M Reduce
Q1 2026 106.37K $47.50M Reduce
Q2 2026 101.62K $51.50M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VRTX and 13F data

VRTX (VERTEX PHARMACEUTICALS INC) is a Health Care company. 33 other funds we track also report a position in VRTX — the largest reported positions include Capital World Investors (US$12.97B), Capital World Investors (US$12.97B), Capital Research Global Investors (US$9.68B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRTX

All VRTX fund holders →

FAQ

How long has Intermede Investment Partners Ltd held VRTX?

Intermede Investment Partners Ltd has disclosed VRTX holdings in 6 of the last 6 reported quarters, going back to Q1 2025.

What is Intermede Investment Partners Ltd's current position in VRTX?

As of Q2 2026, Intermede Investment Partners Ltd holds 101.62K shares of VRTX (VERTEX PHARMACEUTICALS INC), valued at $51.50M, representing 2.17% of its reported portfolio and ranking #22.

Has Intermede Investment Partners Ltd been buying or selling VRTX?

In the latest 13F filing (Q2 2026), Intermede Investment Partners Ltd reduced its position in VRTX.

Which other funds hold VRTX?

Other major institutional holders of VRTX include Capital World Investors, Capital World Investors, Capital Research Global Investors, among 33 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.